165 related articles for article (PubMed ID: 12069991)
1. GF120918, a P-glycoprotein modulator, increases the concentration of unbound amprenavir in the central nervous system in rats.
Edwards JE; Brouwer KR; McNamara PJ
Antimicrob Agents Chemother; 2002 Jul; 46(7):2284-6. PubMed ID: 12069991
[TBL] [Abstract][Full Text] [Related]
2. Effects of a P-glycoprotein inhibitor on brain and plasma concentrations of anti-human immunodeficiency virus drugs administered in combination in rats.
Savolainen J; Edwards JE; Morgan ME; McNamara PJ; Anderson BD
Drug Metab Dispos; 2002 May; 30(5):479-82. PubMed ID: 11950774
[TBL] [Abstract][Full Text] [Related]
3. Effects of a potent and specific P-glycoprotein inhibitor on the blood-brain barrier distribution and antinociceptive effect of morphine in the rat.
Letrent SP; Pollack GM; Brouwer KR; Brouwer KL
Drug Metab Dispos; 1999 Jul; 27(7):827-34. PubMed ID: 10383928
[TBL] [Abstract][Full Text] [Related]
4. Role of P-glycoprotein on the CNS disposition of amprenavir (141W94), an HIV protease inhibitor.
Polli JW; Jarrett JL; Studenberg SD; Humphreys JE; Dennis SW; Brouwer KR; Woolley JL
Pharm Res; 1999 Aug; 16(8):1206-12. PubMed ID: 10468021
[TBL] [Abstract][Full Text] [Related]
5. Clinical pharmacokinetics of doxorubicin in combination with GF120918, a potent inhibitor of MDR1 P-glycoprotein.
Sparreboom A; Planting AS; Jewell RC; van der Burg ME; van der Gaast A; de Bruijn P; Loos WJ; Nooter K; Chandler LH; Paul EM; Wissel PS; Verweij J
Anticancer Drugs; 1999 Sep; 10(8):719-28. PubMed ID: 10573204
[TBL] [Abstract][Full Text] [Related]
6. Enhanced antinociception of the model opioid peptide [D-penicillamine] enkephalin by P-glycoprotein modulation.
Chen C; Pollack GM
Pharm Res; 1999 Feb; 16(2):296-301. PubMed ID: 10100317
[TBL] [Abstract][Full Text] [Related]
7. Effect of GF120918, a potent P-glycoprotein inhibitor, on morphine pharmacokinetics and pharmacodynamics in the rat.
Letrent SP; Pollack GM; Brouwer KR; Brouwer KL
Pharm Res; 1998 Apr; 15(4):599-605. PubMed ID: 9587957
[TBL] [Abstract][Full Text] [Related]
8. Assessment of active transport of HIV protease inhibitors in various cell lines and the in vitro blood--brain barrier.
van der Sandt IC; Vos CM; Nabulsi L; Blom-Roosemalen MC; Voorwinden HH; de Boer AG; Breimer DD
AIDS; 2001 Mar; 15(4):483-91. PubMed ID: 11242145
[TBL] [Abstract][Full Text] [Related]
9. Increased penetration of paclitaxel into the brain by inhibition of P-Glycoprotein.
Kemper EM; van Zandbergen AE; Cleypool C; Mos HA; Boogerd W; Beijnen JH; van Tellingen O
Clin Cancer Res; 2003 Jul; 9(7):2849-55. PubMed ID: 12855665
[TBL] [Abstract][Full Text] [Related]
10. Characterization of phosphine complexes of technetium(III) as transport substrates of the multidrug resistance P-glycoprotein and functional markers of P-glycoprotein at the blood-brain barrier.
Luker GD; Rao VV; Crankshaw CL; Dahlheimer J; Piwnica-Worms D
Biochemistry; 1997 Nov; 36(46):14218-27. PubMed ID: 9369495
[TBL] [Abstract][Full Text] [Related]
11. Assessment of P-glycoprotein activity in the Blood-Brain Barrier (BBB) using Near Infrared Fluorescence (NIRF) imaging techniques.
On NH; Chen F; Hinton M; Miller DW
Pharm Res; 2011 Oct; 28(10):2505-15. PubMed ID: 21598079
[TBL] [Abstract][Full Text] [Related]
12. Role of P-glycoprotein in distribution of nelfinavir across the blood-mammary tissue barrier and blood-brain barrier.
Edwards JE; Alcorn J; Savolainen J; Anderson BD; McNamara PJ
Antimicrob Agents Chemother; 2005 Apr; 49(4):1626-8. PubMed ID: 15793156
[TBL] [Abstract][Full Text] [Related]
13. Increased oral bioavailability of topotecan in combination with the breast cancer resistance protein and P-glycoprotein inhibitor GF120918.
Kruijtzer CM; Beijnen JH; Rosing H; ten Bokkel Huinink WW; Schot M; Jewell RC; Paul EM; Schellens JH
J Clin Oncol; 2002 Jul; 20(13):2943-50. PubMed ID: 12089223
[TBL] [Abstract][Full Text] [Related]
14. Amprenavir: a new human immunodeficiency virus type 1 protease inhibitor.
Fung HB; Kirschenbaum HL; Hameed R
Clin Ther; 2000 May; 22(5):549-72. PubMed ID: 10868554
[TBL] [Abstract][Full Text] [Related]
15. Influence of P-glycoprotein inhibitors on accumulation of macrolides in J774 murine macrophages.
Seral C; Michot JM; Chanteux H; Mingeot-Leclercq MP; Tulkens PM; Van Bambeke F
Antimicrob Agents Chemother; 2003 Mar; 47(3):1047-51. PubMed ID: 12604540
[TBL] [Abstract][Full Text] [Related]
16. Effect of efflux inhibition on brain uptake of itraconazole in mice infected with Cryptococcus neoformans.
Imbert F; Jardin M; Fernandez C; Gantier JC; Dromer F; Baron G; Mentre F; Van Beijsterveldt L; Singlas E; Gimenez F
Drug Metab Dispos; 2003 Mar; 31(3):319-25. PubMed ID: 12584159
[TBL] [Abstract][Full Text] [Related]
17. Amprenavir.
Adkins JC; Faulds D
Drugs; 1998 Jun; 55(6):837-42; discussion 843-4. PubMed ID: 9617598
[TBL] [Abstract][Full Text] [Related]
18. Role of breast cancer resistance protein in the bioavailability and fetal penetration of topotecan.
Jonker JW; Smit JW; Brinkhuis RF; Maliepaard M; Beijnen JH; Schellens JH; Schinkel AH
J Natl Cancer Inst; 2000 Oct; 92(20):1651-6. PubMed ID: 11036110
[TBL] [Abstract][Full Text] [Related]
19. Vitamin E-TPGS increases absorption flux of an HIV protease inhibitor by enhancing its solubility and permeability.
Yu L; Bridgers A; Polli J; Vickers A; Long S; Roy A; Winnike R; Coffin M
Pharm Res; 1999 Dec; 16(12):1812-7. PubMed ID: 10644067
[TBL] [Abstract][Full Text] [Related]
20. Assessing safety and efficacy of directed P-glycoprotein inhibition to improve the pharmacokinetic properties of saquinavir coadministered with ritonavir.
Huisman MT; Smit JW; Wiltshire HR; Beijnen JH; Schinkel AH
J Pharmacol Exp Ther; 2003 Feb; 304(2):596-602. PubMed ID: 12538811
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
